Ocrelizumab modifies circulating immune asset in relapsing-remitting multiple sclerosis subjects

被引：0
|
作者：
Abbadessa, Gianmarco [1 ]
Bruzzaniti, Sara [2 ]
Miele, Giuseppina [1 ]
Piemonte, Erica [3 ]
Signoriello, Elisabetta [1 ]
Lus, Giacomo [1 ]
Matarese, Giuseppe [3 ]
Galgani, Mario [3 ]
Bonavita, Simona [1 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Clin Neurol 2, Naples, Italy
[2] Univ Naples Federico II, Dipartimento Biol, Naples, Italy
[3] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2021年 / 429卷
关键词：
D O I：
10.1016/j.jns.2021.118820
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
118820
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [1] Ocrelizumab Alters the Circulating Metabolome in People with Relapsing-remitting Multiple Sclerosis
    Siavoshi, Fatemeh
    Ladakis, Dimitrios C.
    Muller, Ashley
    Nourbakhsh, Bardia
    Bhargava, Pavan
    ANNALS OF NEUROLOGY, 2024, 96 : S92 - S93
  • [2] Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis
    Siavoshi, Fatemeh
    Ladakis, Dimitrios C.
    Muller, Ashley
    Nourbakhsh, Bardia
    Bhargava, Pavan
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (09): : 2485 - 2498
  • [3] Ocrelizumab Alters the Circulating Metabolome in People with Relapsing-remitting Multiple Sclerosis
    Siavoshi, Fatemeh
    Ladakis, Dimitrios
    Muller, Ashley
    Nourbakhsh, Bardia
    Bhargava, Pavan
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 40 - 40
  • [4] Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis
    Menge, Til
    Dubey, Divyanshu
    Warnke, Clemens
    Hartung, Hans-Peter
    Stuve, Olaf
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1131 - 1139
  • [5] Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
    Roos, Izanne
    Hughes, Stella
    McDonnell, Gavin
    Malpas, Charles B.
    Sharmin, Sifat
    Boz, Cavit
    Alroughani, Raed
    Ozakbas, Serkan
    Buzzard, Katherine
    Skibina, Olga
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Kuhle, Jens
    Terzi, Murat
    Laureys, Guy
    Van Hijfte, Liesbeth
    John, Nevin
    Grammond, Pierre
    Grand'Maison, Francois
    Soysal, Aysun
    Jensen, Ana Voldsgaard
    Rasmussen, Peter Vestergaard
    Svendsen, Kristina Bacher
    Barzinji, Ismael
    Nielsen, Helle Hvilsted
    Sejbaek, Tobias
    Prakash, Sivagini
    Stilund, Morten Leif Munding
    Weglewski, Arkadiusz
    Issa, Nadia Mubder
    Kant, Matthias
    Sellebjerg, Finn
    Gray, Orla
    Magyari, Melinda
    Kalincik, Tomas
    MSBase Study Grp
    Danish MS Registry Study Grp
    JAMA NEUROLOGY, 2023, 80 (08) : 789 - 797
  • [6] Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
    Hartung, Hans-Peter
    Benedict, Ralph H. B.
    Berger, Thomas
    Bermel, Robert A.
    Brochet, Bruno
    Carroll, William M.
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Nos, Carlos
    Patti, Francesco
    Perrin Ross, Amy
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Wuerfel, Jens
    Clinch, Susanne
    Kadner, Karen
    Kuenzel, Thomas
    Kulyk, Inessa
    Raposo, Catarina
    Thanei, Gian-Andrea
    Killestein, Joep
    NEUROLOGY, 2024, 103 (12)
  • [7] Real world experience with ocrelizumab in patiens with relapsing-remitting multiple sclerosis
    Lopez Ruiz, R.
    Dotor Garcia-Soto, J.
    Hiraldo, J. D. G.
    Ruiz-Pena, J. L.
    Paramo Camino, M. D.
    Ruiz De Arcos, M.
    Navarro Mascarell, G.
    Eichau Madueno, S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 301 - 301
  • [8] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [9] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
  • [10] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
12345